Navigation Links
Oxygen Biotherapeutics, Inc. Establishes Warfighter Division
Date:3/24/2009

Hires Army Veteran to Lead It

COSTA MESA, Calif., March 24 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced it has hired Army Reserve officer Kirk Harrington, a Special Operations Force field-grade officer, diplomat, and government advisor as head of its newly-established warfighter division.

Harrington is an 18-year army veteran who in 2006 was appointed by the United States Department of State as a senior adviser to the Government of Iraq. As the sole diplomat to the Iraqi Ministries of Transportation and Construction and Housing, he oversaw every facet of Iraqi reconstruction efforts to include new implementation of roads and bridges, ports, airfields and railroads. His background includes lecturing on Middle Eastern affairs at the US Military Academy, West Point and he is a founding member of Emerging Foreign Market Collaboration, LLC., a New York-based government consulting firm.

The new warfighter division is a result of the Purple Heart Injury Laboratory (PHIL) initiative between the company and Virginia Commonwealth University announced last month to establish a federal defense appropriation-funded joint venture focusing on developing new treatments for military battlefield injuries. PHIL will be jointly managed and operated research laboratories focusing on healing battlefield injuries with new therapies and concepts.

"Kirk's role will be to connect the company with military research efforts and help us with sources of government funding for the military-related applications of Oxycyte(R) such as blast-related TBI, decompression sickness, and wound treatment. It's my expectation that Kirk's efforts will be more than self-supporting and that this division will become an important revenue generator for the company," said Chris J. Stern, company chairman and CEO. "He has outstanding contacts in the Department of Defense and other parts of the federal government along with a disciplined approach to getting things done. I'm looking forward to Kirk putting those assets to work in helping the company with its product development plans."

"I know only too well about the devastating effects of blast-related TBI and other wounds suffered by our military personnel. I believe Oxycyte can help them have a better and faster recovery and I want to help make it available as fast as possible. I'm excited about being a part of this with Oxygen Biotherapeutics," said Harrington.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes. More information is available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to the expectations for the company's new Warfighter Division and the role of the employee hired to lead it. Actual events or results may differ from Oxygen Biotherapeutics, Inc.'s expectations. There can be no assurance that the new employee will have any success in generating funding for the company from any U. S. Government source, that the new division will be financially self-supporting, or that it will generate any meaningful revenue for the company. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ozone/Oxygen Shot Helps Heal Herniated Disk
2. OxygenToGo Is Poised To Help Airlines Struggling With New Portable Oxygen Concentrator Regulations From The U.S. DOT
3. Oxygen4Energy: International Sports News - World Anti-Doping Agency (WADA) Bans Oxygen Use
4. Calling Policies Unreasonable, 123 Members of Congress Press for Changes in Medicare Home Oxygen Policies for Emergency Care, Supplies and Other Obligations After 36 Months of Service
5. An atmosphere rich in CO2 and oxygen enhances the quality of refrigerated potato
6. As Congress Debates Competitive Bidding Program, Home Oxygen Beneficiaries and Providers Left to Cope with 27 Percent Cut to Medicare Home Oxygen Benefit
7. Worm provides clues about preventing damage caused by low-oxygen during stroke, heart attack
8. Low Cost Oxygen Regulator: Pay Less For Quality
9. Study of Everest Climbers Questions Oxygen Use
10. Massive Cuts to Medicare Home Oxygen Therapy Benefit Taking Effect January 1 Creating Acute Anxiety Among Beneficiary and Provider Communities
11. Facing Deadly Ice Storms, Home Medical Equipment Providers in New England Mobilize to Protect Oxygen Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... “Vinaya” Rednam distinguishes herself once more by being among Houston’s first plastic surgeons ... the highest quality plastic surgery care without disrupting busy schedules and maintaining the ...
(Date:8/17/2017)... ... August 17, 2017 , ... Florida Hospital Zephyrhills showcased ... community partners. The newly renovated ER was designed with patients in mind and ... semi-private rooms to deliver patient results, improve efficiencies and reduce length of stay, ...
(Date:8/17/2017)... ... August 17, 2017 , ... With the introduction of new devices, new features, ... changes to the smartwatch market. As of June 2017, nearly nine percent of U.S. ... months prior. Additionally, according to latest WEAR Report Industry Overview and Forecast from NPD’s ...
(Date:8/17/2017)... ... 17, 2017 , ... Pot Valet is a leading provider of premium medical-grade ... the state, and soon, every state in the country, the company offers patients safe, ... dispensary altogether. , According to Pot Valet, all California patients have the ...
(Date:8/17/2017)... VA (PRWEB) , ... August 17, 2017 , ... ... for Great Employers , an international competition, were announced today. The awards recognize ... products and suppliers who help to create and drive great places to work. ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/27/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST ) ... and updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a ... sales at constant currency (organic) grew by 3.9%. ... to $0.60 in the prior-year quarter. Second-quarter 2017 adjusted ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
Breaking Medicine Technology: